BridgeBio Pharma: Taking Some Profits (NASDAQ:BBIO) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
BridgeBio Pharma (BBIO) said the first patient with non-small cell lung cancer ((NSCLC)) was dosed in a phase 1/2 trial of BBP-398 with Bristol Myers Squibb's (BMY) Opdivo (nivolumab).
Xortx Therapeutics (XRTXF) (XRTX) reported data from a bridging pharmacokinetics trial of its proprietary formulation of oral oxypurinol, Xorlo being explored for kidney disease.The.
Relief Therapeutics (RLFTF)(RLFTD) reported six-month stability data on a new formulation of potential lung disease therapy RLF-100 (aviptadil).The company said the data showed high.
Galapagos has a new CEO since April 2022. The new strategy is taking shape with some research programs scrapped and small assets acquired. Read more here.